BSc PhD CChem FRSC Member ACS FHEA
Jeremy Everett is the Professor of Pharmaceutical Technologies at the University of Greenwich, Chatham Maritime, Visiting Professor in the Department of Surgery and Cancer at Imperial College, London and Visiting Professor, Scientific Consultant and currently the Acting Director of the Singapore Phenome Centre at Nanyang Technological University, Singapore. He previously held a variety of global drug discovery technology leadership positions for Pfizer, and before that, SmithKline Beecham, including responsibility for drug target analysis, drug design, lead generation, analytical sciences, biobanking, screening file management, high throughput screening (HTS), and structural biology. He is a consultant on drug discovery to both large pharma and small research institutes and has worked as an expert witness in pharmaceutical patent litigation in the USA and Europe.
Jeremy is experienced in the application of metabolic profiling to personalized medicine, drug metabolism, toxicology and systems biology i.e. metabonomics. His research is currently focused in two areas of metabonomics: (1) biomarkers of leanness and insulin sensitivity, and the discovery of genome - microbiome - phenotype interactions in a genetically modified mouse of potential importance in obesity and diabetes and (2) understanding genome - metabonome interactions in genetically modified human cancer cells. He is a co-leader of the Medway Metabonomics Research Group (MMRG) at the University of Greenwich. He has over 90 publications and an h-index of 25.